Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.

Abstract: Described herein are compounds which have the general formula: ##STR1## or a prodrug or pharmaceutically acceptable salt, solvate or hydrate thereof wherein:R.sup.1 is selected from the group consisting of H, alkyl and the counter ion for a basic addition salt;X is selected from the group consisting of CR.sup.9 R.sup.10, S, O, SO, SO.sub.2, NH and N-alkyl;R.sup.2, R.sup.3, R.sup.4, R.sup.9 and R.sup.10 are independently selected from the group consisting of H and alkyl;R.sup.5 and R.sup.6 are independently selected from the group consisting of H, alkyl and phenyl, or, alternatively, R.sup.5 and R.sup.6 together may form a methylene group or a 3- to 6-membered a spirocyclic group;wherein, when X is CR.sup.9 R.sup.10, one or both pairs of R.sup.5 and R.sup.9 or R.sup.6 and R.sup.10 may join to form a double or triple bondR.sup.7 is selected from the group consisting of Formula II-V: ##STR2## which are all optionally substituted, at nodes other than R.sup.

Abstract: Provided are, among other things, nucleic acid sequences encoding the GlyT1d form of glycine transporter, vectors, methods of producing the transporter, and methods for identifying bioactive agents.

Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the following formulas I and II: ##STR1## or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to materials and methods for the identification of agents that regulate glycine transport in or out of cells, particularly in or out of neuronal and neuronal-associated cells. Such materials include non-mammalian cells having transfected therein a glycine transporter. The methods relate to the manipulation of such cells such that agents are identified that cause intake or outflow of glycine with respect to a given glycine transporter.

Abstract: The invention provides nucleic acids and proteins derived from the sequence of the human GlyT-2 transporter of the amino acid glycine.

Abstract: The present invention relates to materials and methods for the identification of agents that regulate glycine transport in or out of cells, particularly in or out of neuronal and neuronal-associated cells. Such materials include non-mammalian cells having transfected therein a glycine transporter. The methods relate to the manipulation of such cells such that agents are identified that cause intake or outflow of glycine with respect to a given glycine transporter.